| HOME >> BIOLOGY >> TECHNOLOGY |
"It is the strategy of the Company to add value to its oncology program by expanding the utility of Hypocrellin-based products for Immuno Photodynamic Therapy and Sonodynamic Therapy applications", said Dr. Madi R. Madiyalakan, CEO of the Company. "The current funding from NRC/IRAP, and recently signed collaborative research agreement with British Columbia Cancer Agency will help us accomplish that objective in an efficient manner", added Dr. Madiyalakan.
The Company also announces that it has retained the consulting services of Dr. Graeme Boniface to help accelerate its clinical trial program. Dr. Boniface was previously Senior Director of Clinical research at QLT Inc. in Vancouver, where he led the clinical development of several photosensitizers for oncology indications. Dr. Boniface brings more than 25 years of experience in conducting clinical trials throughout the world. Additionally, the Company believes that its partnership with Paramount Biosciences for dermatology program will help achieve its long-term growth objectives, including additional clinical trials for dermatology applications.
About Quest PharmaTech Inc: Quest PharmaTech Inc. is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.
"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."
| SOURCE Quest PharmaTech Inc. Copyright©2008 PR Newswire. All rights reserved |